Nucleic acid nanobiosystems for cancer theranostics: an overview of emerging trends and challenges

Different cancers remain major global health challenges due to their diverse biological behaviors and significant treatment hurdles. The aging of populations and lifestyle factors increase cancer occurrence and place increasing pressure on healthcare systems. Despite continuous advancements, many cancers remain fatal due to late-stage diagnosis, tumor heterogeneity, and drug resistance, thus necessitating urgent development of innovative treatment solutions. Therapeutic nucleic acids, a new class of biological drugs, offer a promising approach to overcoming these challenges. The recent Nucleic Acids and Nanobiosystems in Cancer Theranostics (NANCT) conference brought together internationally recognized experts from 15 countries to discuss cutting-edge research, spanning from oncolytic viruses to anticancer RNA nanoparticles and other emerging nanotechnologies. This review captures key insights and developments, emphasizing the need for interdisciplinary translation of scientific advancements into clinical practice and shaping the future of personalized cancer treatments for improved therapeutic outcomes.